RxDoctor Payments Data

Margaret Throckmorton, APRN

Psychiatric/Mental Health · Lewisburg, TNNPI 1902372790

Payments from drug & device makers

$3,114in general payments, 2019–2025

Across 39 payments — averaging $79.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$2K
  • Neurocrine Biosciences, Inc.$551
  • Axsome Therapeutics, Inc.$358
  • Johnson & Johnson$245
  • Otsuka America Pharmaceutical, Inc.$134
  • AbbVie$74
  • plus $152 from 4 others

What the payments were for

  • Travel & lodging$83827%
  • Food & beverage$2,27673%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,114 in reported general payments places this provider in the 80th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,093
Medicare patients
56
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate29$230,317
Invega SustennaPaliperidone Palmitate44$92,703
VraylarCariprazine Hcl20$27,150
TrintellixVortioxetine Hydrobromide18$8,501
Divalproex Sodium ErDivalproex Sodium128$7,501
BelsomraSuvorexant12$5,367
Lurasidone Hcl30$4,866
Aripiprazole101$3,278
Perphenazine60$3,210
Quetiapine Fumarate275$3,046
Olanzapine55$2,177
Vilazodone Hcl13$2,153
Duloxetine Hcl56$2,139
Haloperidol63$1,791
Clozapine12$1,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$551$230,31729 claims
Johnson & JohnsonInvega Sustenna$245$92,70344 claims
AbbVieVraylar$74$27,15020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Lewisburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →